Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Agomelatine for sleep disturbance in autism spectrum disorder
2011-003313-42Phase 2Active
- Sponsor
- Hospital General Universitario de Alicante
- Start
- Nov 2011
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, single-arm trial of agomelatine in sleep disorder and Autism Spectrum Disorder (ASD), sponsored by Hospital General Universitario de Alicante. Primary endpoint: TAP variable. Started Nov 2011; status: active.
02
Drugs
agomelatine
03
Conditions
sleep disorderAutism Spectrum Disorder (ASD)
Beyond the preview
Go deeper on 2011-003313-42.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2011-003313-42.